Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis

被引：10

作者：

Marchetti, Claudia ^{[1
]}

De Felice, Francesca ^{[2
]}

Musella, Angela ^{[1
]}

Palaia, Innocenza ^{[1
]}

Monti, Marco ^{[1
]}

Musio, Daniela ^{[2
]}

Muzii, Ludovico ^{[1
]}

Tombolini, Vincenzo ^{[2
]}

Panici, Pierluigi Benedetti ^{[1
]}

机构：

[1] Sapienza Univ Rome, Dept Gynecol & Obstet Sci & Urol Sci, Rome, Italy

[2] Sapienza Univ Rome, Policlin Umberto 1, Dept Radiotherapy, Rome, Italy

来源：

ONCOTARGET | 2016年 / 7卷 / 36期

关键词：

ovarian cancer; dose-dense; carboplatin; paclitaxel; weekly; ADVANCED EPITHELIAL OVARIAN; PHASE-III TRIAL; CONVENTIONAL PACLITAXEL; 1ST-LINE TREATMENT; OPEN-LABEL; CARBOPLATIN;

D O I：

10.18632/oncotarget.11094

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a meta-analysis to compare the two regimens. Method: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity. Results: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77-1.16, p=0.06), as well as in term of severe acute toxicity. Conclusion: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.

引用

页码：58709 / 58715

页数：7

共 16 条

[1]

[Anonymous], SGO ANN M

[2]

[Anonymous], SGO ANN M

[3] OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].

BEGG, CB ;

MAZUMDAR, M .

BIOMETRICS, 1994, 50 (04) :1088-1101

[4] Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer [J].

Chan, J. K. ;

Brady, M. F. ;

Penson, R. T. ;

Huang, H. ;

Birrer, M. J. ;

Walker, J. L. ;

DiSilvestro, P. A. ;

Rubin, S. C. ;

Martin, L. P. ;

Davidson, S. A. ;

Huh, W. K. ;

O'Malley, D. M. ;

Boente, M. P. ;

Michael, H. ;

Monk, B. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (08) :738-748

[5] Individual patient data meta-analyses in cancer [J].

Clarke, M ;

Stewart, L ;

Pignon, JP ;

Bijnens, L .

BRITISH JOURNAL OF CANCER, 1998, 77 (11) :2036-2044

[6] Bias in meta-analysis detected by a simple, graphical test [J].

Egger, M ;

Smith, GD ;

Schneider, M ;

Minder, C .

BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634

[7] A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer [J].

Gao, Guanghui ;

Chu, Haiqing ;

Zhao, Lan ;

Gui, Tao ;

Xu, Qinghua ;

Shi, Jianping .

LUNG CANCER, 2012, 76 (03) :380-386

[8] Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016) [J].

Harano, K. ;

Terauchi, F. ;

Katsumata, N. ;

Takahashi, F. ;

Yasuda, M. ;

Takakura, S. ;

Takano, M. ;

Yamamoto, Y. ;

Sugiyama, T. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :251-257

[9] Measuring inconsistency in meta-analyses [J].

Higgins, JPT ;

Thompson, SG ;

Deeks, JJ ;

Altman, DG .

BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :557-560

[10] Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial [J].

Katsumata, Noriyuki ;

Yasuda, Makoto ;

Isonishi, Seiji ;

Takahashi, Fumiaki ;

Michimae, Hirofumi ;

Kimura, Eizo ;

Aoki, Daisuke ;

Jobo, Toshiko ;

Kodama, Shoji ;

Terauchi, Fumitoshi ;

Sugiyama, Toru ;

Ochiai, Kazunori .

LANCET ONCOLOGY, 2013, 14 (10) :1020-1026

← 1 2 →